Evidence map›Paper›PMID 42202786›Full record

ArticleCell reports methods2026

Real-time cell viability monitoring for high-throughput drug screening using tumor xenograft-derived cells.

Elham Esmaeilishirazifard, Daniel Guerrero-Romero, Allan J W Lui, Abigail Shea, Long V Nguyen, Maurizio Callari, Riccardo Masina, Kevin Tu, Richard Baird, Paul Edwards and 7 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cell reports methods, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors.

Elham EsmaeilishirazifardCancer Research UK Cambridge Institute, Li Ka Shing Centre, University of Cambridge, Cambridge CB2 0RE, UK; Merck Life Science UK Limited, Gillingham SP8 4XT, UK.
Daniel Guerrero-RomeroCancer Research UK Cambridge Institute, Li Ka Shing Centre, University of Cambridge, Cambridge CB2 0RE, UK.
Allan J W LuiCancer Research UK Cambridge Institute, Li Ka Shing Centre, University of Cambridge, Cambridge CB2 0RE, UK.
Abigail SheaCancer Research UK Cambridge Institute, Li Ka Shing Centre, University of Cambridge, Cambridge CB2 0RE, UK; Centre for Evolution and Cancer, Division of Molecular Pathology, The Institute of Cancer Research, Sutton, UK.
Long V NguyenCancer Research UK Cambridge Institute, Li Ka Shing Centre, University of Cambridge, Cambridge CB2 0RE, UK; Princess Margaret Cancer Centre, University Health Network, Toronto, ON M5G 2M9, Canada; Department of Medicine, and Department of Medical Biophysics, University of Toronto, Toronto, ON M5S 3H2, Canada.
Maurizio CallariCancer Research UK Cambridge Institute, Li Ka Shing Centre, University of Cambridge, Cambridge CB2 0RE, UK; Fondazione Michelangelo, Milan, Italy.
Riccardo MasinaCancer Research UK Cambridge Institute, Li Ka Shing Centre, University of Cambridge, Cambridge CB2 0RE, UK.
Kevin TuCancer Research UK Cambridge Institute, Li Ka Shing Centre, University of Cambridge, Cambridge CB2 0RE, UK.
Richard BairdDepartment of Oncology, University of Cambridge, Cambridge, CB2 0AH, UK.
Paul EdwardsCancer Research UK Cambridge Institute, Li Ka Shing Centre, University of Cambridge, Cambridge CB2 0RE, UK.
Wendy GreenwoodCancer Research UK Cambridge Institute, Li Ka Shing Centre, University of Cambridge, Cambridge CB2 0RE, UK; Varsity Pharmaceuticals Ltd, Cambridge, UK.
Steve FullerVarsity Pharmaceuticals Ltd, Cambridge, UK.
Claire CrafterBioscience, R&D Oncology, AstraZeneca, Cambridge, UK.
Mandy LawsonBioscience, R&D Oncology, AstraZeneca, Cambridge, UK.
Alejandra BrunaCancer Research UK Cambridge Institute, Li Ka Shing Centre, University of Cambridge, Cambridge CB2 0RE, UK; Centre for Evolution and Cancer, Division of Molecular Pathology, The Institute of Cancer Research, Sutton, UK.
Oscar M RuedaMRC-Biostatistics Unit, University of Cambridge, School of Clinical Medicine, Cambridge CB2 0SR, UK. Electronic address: oscar.rueda@mrc-bsu.cam.ac.uk.
Carlos CaldasDepartment of Clinical Biochemistry and Institute of Metabolic Science, University of Cambridge, Cambridge, UK; Department of Immunology and Cancer Research, Faculty of Medicine, Hebrew University of Jerusalem, Jerusalem, Israel. Electronic address: cc234@cam.ac.uk.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Patient-derived tumor xenografts (PDTXs) recapitulate the molecular and phenotypic heterogeneity of human cancers, making them valuable pre-clinical models for cancer drug development. However, high-throughput drug screening (HTDS) using ex vivo short-term cultures of PDTX-derived tumor cells (PDTCs) is hindered by endpoint viability assays that provide only static measures of drug response. Here, we establish an optimized a screening platform by validating the RealTime-Glo (RTG) bioluminescent assay for dynamic, real-time measurements of PDTC viability. We further introduce an analytical metric to quantify drug responses independent of cell growth rate. Using this approach, we screened 67 compounds across 43 breast cancer PDTCs and revealed model-specific pharmacodynamic heterogeneity. Our PDTC-based HTDS pipeline improves assay robustness and offers an enhanced platform for leveraging patient-derived xenograft models in precision medicine.

Indexed as

Antineoplastic AgentsBreast NeoplasmsHigh-Throughput Screening AssaysXenograft Model Antitumor AssaysAnimalsCell Line, TumorCell SurvivalDrug Screening Assays, AntitumorFemaleHumansMiceAntineoplastic Agentsbreast cancerCP: cancer biologydrug response kineticsdynamic viability monitoringex vivo drug sensitivityhigh-throughput drug screeningisotonic regression modelingpatient-derived tumor xenograftsPDTCsPDTX-derived tumor cellsPDTXspharmacodynamic profilingreal-time viability monitoring

Identifiers

PMID42202786
PMCPMC13389979

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.